

INFORMATION FOR HEALTHCARE PROVIDERS



This patient has received FUCASO suspension for infusion, an autologous CAR-T cell therapy. Following FUCASO treatment, cytokine release syndrome can happen. It may include neurological toxicities. Treatment with FUCASO may result in a false-positive HIV test result. This patient should not donate blood, organs, tissues, or cells. This patient may develop secondary malignancies, including those of T-cell origin. In such cases, healthcare providers are advised to contact Nanjing IASO Medical Technology Co., Ltd. at **PV@iasobio.com** for instructions on collection of patient samples for testing.

Before providing any treatment,
call the treating physician at the number on the front of the card.

Healthcare providers are encouraged to report serious adverse events related to the use of FUCASO to Nanjing IASO Medical Technology Co., Ltd. at **PV@iasobio.com**, or the Vigilance and Compliance Branch, Health Sciences Authority online at **<https://www.hsa.gov.sg/adverse-events>**.

When reporting possible adverse events, please include the individual Batch ID printed on the front of this card.

Document Version Number: 3.0

This document has been approved by HSA as of 18-Jun-2026

PATIENT ALERT CARD



Carry this card with you at all times

Be sure to tell all your healthcare providers that you are being treated with FUCASO
and SHOW THEM THIS CARD

My name is: _____

I have been treated with FUCASO (equecabtagene autoleucl), a CAR-T cell therapy containing genetically modified autologous T cells.

Batch ID: _____ **Date of infusion:** _____

FUCASO treating physician's name and contact details: _____

Before providing any treatment, please call my treating doctor at the number above.
I should not donate blood, organs, tissues, or cells.

FUCASO may cause side effects that are severe or life-threatening. Tell your treating doctor immediately or go to the hospital's emergency department if you experience any of the following side effects:



- > Fever (38°C or higher)
- > Chills or shaking chills
- > Fast or irregular heartbeat
- > Difficulty breathing
- > Very low blood pressure
- > Dizziness/light headedness
- > Feeling confused, less alert, or disoriented, having difficulty speaking or slurred speech, having difficulty reading, writing, and understanding words, memory loss
- > Loss of coordination affecting movement and balance, slower movements, changes in handwriting
- > Personality changes including a reduced ability to express emotions, being less talkative, disinterest in activities, and reduced facial expression
- > Tingling, numbness, and pain of hands and feet, difficulty walking, leg and/or arm weakness
- > Facial numbness, difficulty moving muscles of face and eyes

INFORMATION FOR PATIENT



After getting FUCASO,

You will be monitored at the certified healthcare facility where you received your treatment for **at least 14 days**.

You should plan to stay close to the location where you received your treatment for **at least 4 weeks**.

Do not drive, or operate heavy machinery, or do other activities that could be dangerous if you are not mentally alert, for **at least 8 weeks**.